| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non–Small-Cell Lung Cancer
|
Concannon, Kyle F.
|
|
|
25 |
7 |
p. 601-611
|
artikel
|
| 2 |
Association Between Utilization of Services and Perioperative Outcomes for Lung Cancer Resection
|
Thosani, Darshak S.
|
|
|
25 |
7 |
p. e330-e336
|
artikel
|
| 3 |
Association of Serum Biomarkers With Neurocognitive Decline After PCI in Small Cell Lung Cancer: An Exploratory Study of the Phase III NCT01780675 Trial
|
Zeng, Haiyan
|
|
|
25 |
7 |
p. 653-659.e1
|
artikel
|
| 4 |
Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.
|
Rousseau, Guillaume
|
|
|
25 |
7 |
p. e323-e329
|
artikel
|
| 5 |
Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer
|
Sridhar, Arthi
|
|
|
25 |
7 |
p. e286-e294
|
artikel
|
| 6 |
Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort
|
Bodor, J. Nicholas
|
|
|
25 |
7 |
p. e312-e315.e1
|
artikel
|
| 7 |
Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections
|
Somisetty, Medha
|
|
|
25 |
7 |
p. 612-618
|
artikel
|
| 8 |
Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons
|
Garcia, Christine
|
|
|
25 |
7 |
p. 634-642
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
25 |
7 |
p. A1
|
artikel
|
| 10 |
Efficacy of Systemic Treatments in Patients With Metastatic Lung Invasive Mucinous Adenocarcinoma
|
Demir, Tarık
|
|
|
25 |
7 |
p. e316-e322
|
artikel
|
| 11 |
Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma
|
Schmid, Sabine
|
|
|
25 |
7 |
p. e277-e285.e3
|
artikel
|
| 12 |
Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy
|
Murata, Saori
|
|
|
25 |
7 |
p. e369-e378.e3
|
artikel
|
| 13 |
Implementation of an Electronic Medical Record Alert Significantly Increases Lung Cancer Screening Uptake
|
Park, Ju Ae
|
|
|
25 |
7 |
p. 619-623
|
artikel
|
| 14 |
Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis
|
Soto-Lanza, Felipe
|
|
|
25 |
7 |
p. 624-633.e2
|
artikel
|
| 15 |
Prehabilitation for Older Adults Undergoing Lung Cancer Surgery: A Literature Review and Needs Assessment
|
Zhao, Jane Y.
|
|
|
25 |
7 |
p. 595-600
|
artikel
|
| 16 |
Primary Stereotactic Body Radiotherapy for Spinal Bone Metastases From Lung Adenocarcinoma
|
Chou, Kuan-Nien
|
|
|
25 |
7 |
p. e337-e347
|
artikel
|
| 17 |
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)
|
Kawachi, Hayato
|
|
|
25 |
7 |
p. 643-652.e4
|
artikel
|
| 18 |
Routes to Diagnosis in Danish Lung Cancer Patients: Emergency Presentation, Age and Smoking History—A Population-Based Cohort Study
|
Christensen, Niels Lyhne
|
|
|
25 |
7 |
p. e348-e356
|
artikel
|
| 19 |
Table of Contents
|
|
|
|
25 |
7 |
p. A3-A6
|
artikel
|
| 20 |
The Design for a Phase II, Randomized, Multicenter Study of CtDNA-Guided Treatment With Furmonertinib Combined Therapy or Furmonertinib Alone for Untreated Advanced EGFR Mutant Non–small-cell Lung Cancer Patients: The FOCUS-C Study
|
Zhang, Yaxiong
|
|
|
25 |
7 |
p. e357-e361.e17
|
artikel
|
| 21 |
Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis
|
Tanvetyanon, Tawee
|
|
|
25 |
7 |
p. e304-e311
|
artikel
|
| 22 |
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer
|
Reck, Martin
|
|
|
25 |
7 |
p. e362-e368
|
artikel
|
| 23 |
Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK‐Positive Non‐small Cell Lung Cancer
|
Lu, Shun
|
|
|
25 |
7 |
p. e295-e303.e4
|
artikel
|
Tijdschrift beschrijving